Cardiovascular outcomes with sodium–glucose cotransporter-2 inhibitors vs other glucose-lowering drugs in 13 countries across three continents: analysis of CVD-REAL data

Autor: Kamlesh Khunti, Mikhail Kosiborod, Dae Jung Kim, Shun Kohsaka, Carolyn S. P. Lam, Su-Yen Goh, Chern-En Chiang, Jonathan E. Shaw, Matthew A. Cavender, Navdeep Tangri, Josep Franch-Nadal, Reinhard W. Holl, Marit E. Jørgensen, Anna Norhammar, Johan G. Eriksson, Francesco Zaccardi, Avraham Karasik, Dianna J. Magliano, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Johan Bodegård, Filip Surmont, Peter Fenici, the CVD-REAL Investigators and Study Group

Publikováno v: Cardiovascular Diabetology, Vol 20, Iss 1, Pp 1-15 (2021)

Abstract Background Randomized, controlled cardiovascular outcome trials may not be fully representative of the management of patients with type 2 diabetes across different geographic regions. We conducted analyses of data from the multinational CVD-

Externí odkaz: https://doaj.org/article/84b501fd6bee4a8d9bef97cb73d7d10c

Contemporary Trends and Outcomes of Percutaneous and Surgical Aortic Valve Replacement in Patients With Cancer

Autor: Avirup Guha, Amit K. Dey, Sameer Arora, Matthew A. Cavender, John P. Vavalle, Joseph F. Sabik, Ernesto Jimenez, Hani Jneid, Daniel Addison

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 2 (2020)

Background Patients with cancer and severe aortic stenosis are often ineligible for surgical aortic valve replacement (SAVR). Patients with cancer may likely benefit from emerging transcatheter aortic valve replacement (TAVR), given its minimally inv

Externí odkaz: https://doaj.org/article/a3a7fdc971db418bae024ebe86d5588b

Differences in Inpatient Outcomes After Surgical Aortic Valve Replacement at Transcatheter Aortic Valve Replacement (TAVR) and Non‐TAVR Centers

Autor: Godly Jack, Sameer Arora, Paula D. Strassle, Kranthi Sitammagari, Kishorbhai Gangani, Michael Yeung, Matthew A. Cavender, Patrick T. O'Gara, John P. Vavalle

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 22 (2019)

Background Transcatheter aortic valve replacement (TAVR) has solidified the importance of a heart team and revolutionized patient selection for surgical aortic valve replacement (SAVR). It is unknown if hospital ability to offer TAVR impacts SAVR out

Externí odkaz: https://doaj.org/article/ff2c10dab2be4c26acc45fa72bf7783f

Author response for 'Lower risk of cardiovascular events and death associated with initiation of SGLT ‐2 inhibitors versus sulphonylureas – Analysis from the CVD‐REAL 2 study'

Autor: null Su‐Yen Goh, null Mikhail N Kosiborod, null Carolyn S. P. Lam, null Matthew A. Cavender, null Shun Kohsaka, null Anna Norhammar, null Kare I Birkeland, null Reinhard W Holl, null Dídac Mauricio, null Navdeep Tangri, null Jonathan E Shaw, null Marcus Thuresson, null Peter Fenici, null Dae Jung Kim, null M Kosiborod, null MA Cavender, null JP Wilding, null K Khunti, null A Norhammar, null K Birkeland, null ME Jørgensen, null RW Holl, null CSP Lam, null HL Gulseth, null B Carstensen, null E Bollow, null J Franch‐Nadal, null LAG Rodríguez, null A Karasik, null N Tangri, null S Kohsaka, null DJ Kim, null J Shaw, null S Arnold, null SY Goh, null CE Chiang, null JG Eriksson, null F Zaccardi, null P Fenici, null J Bodegård, null H Chen, null F Surmont, null R Kendrick, null W Belli, null ET Wittbrodt, null M Saathoff, null Y Noguchi, null D Tan, null M Williams, null HW Lee, null M Greenbloom, null O Kaidanovich‐Beilin, null K Andersson‐Sundell, null KK Yeo, null YM Bee, null J Khoo, null A Koong, null YH Lau, null F Gao, null WB Tan, null HA Kadir, null KH Ha, null J Lee, null G Chodick, null CM Cohen, null R Whitlock, null LC Soriano, null JA Menzin, null M Guthrie, null J Ilomaki, null D Magliano, null F Hoti, null S Christopher, null M Vehkala, null the CVD‐REAL Investigators and Study Group, null Cantero OF

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a2b9ef53181c174bb6291452d0db1b4b
https://doi.org/10.1111/dom.15092/v2/response1

Impact of Type 2 Myocardial Infarction (MI) on Hospital‐Level MI Outcomes: Implications for Quality and Public Reporting

Autor: Sameer Arora, Paula D. Strassle, Arman Qamar, Evan N. Wheeler, Alexandra L. Levine, Jacob A. Misenheimer, Matthew A. Cavender, George A. Stouffer, Prashant Kaul

Publikováno v: Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 7 (2018)

BackgroundThe International Classification of Diseases (ICD) coding system does not recognize type 2 myocardial infarction (MI) as a separate entity; therefore, patients with type 2 MI continue to be categorized under the general umbrella of non–ST

Externí odkaz: https://doaj.org/article/45ec029b80b44b1bbcd2633f8f7891dc